Trial Profile

A Phase 1/2 Study of Nab-Sirolimus With Pazopanib (VOTRIENT®) in Patients With Advanced Nonadipocytic Soft-Tissue Sarcomas

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 08 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pazopanib (Primary) ; Sirolimus (Primary)
Indications Soft tissue sarcoma
Focus Adverse reactions; Therapeutic Use

Most Recent Events

30 Apr 2025 Status changed from active, no longer recruiting to discontinued. Reason the study was stopped: Study was terminated at completion of the Phase 1 dose escalation due to loss of financial support.
06 Jun 2023 Results (n=19) assessing safety and efficacy of sirolimus combined with pazopanib in patients with advanced soft tissue sarcoma presented at the 59th Annual Meeting of the American Society of Clinical Oncology
25 May 2023 Results presented in an Aadi Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com